| Univariable analysis | Multivariate analysis | ||
---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | |
Age | 1.01 (0.99–1.04) | 0.395 |  |  |
Gender | Â | 0.02 | Â | 0.065 |
 Female | Reference |  | Reference |  |
 Male | 5.36 (1.3–22.07) |  | 3.81 (0.918–15.8) |  |
T stage | Â | 0.658 | Â | Â |
 T1-2 | Reference |  |  |  |
 T3-4 | 0.88 (0.51–1.53) |  |  |  |
N stage | Â | 0.072 | Â | Â |
 N1 | Reference |  |  |  |
 N2-3 | 2.92 (0.91–9.42) |  |  |  |
Liver involvement | Â | 0.03 | Â | 0.039 |
 No | Reference |  | Reference |  |
 Yes | 1.87 (1.06–3.31) |  | 1.94 (1.031–3.64) |  |
Metastatic site | Â | 0.155 | Â | Â |
 Single | Reference |  |  |  |
 Multiple | 1.53 (0.85–2.75) |  |  |  |
Number of metastasis | Â | 0.016 | Â | Â |
 < 4 | Reference |  |  |  |
 ≥ 4 | 1.94 (1.13–3.34) |  |  |  |
LDH | Â | 0.017 | Â | 0.05 |
 < 229 | Reference |  | Reference |  |
 ≥ 229 | 1.96 (1.13–3.42) |  | 1.81 (1.00–3.28) |  |
SUVmax-T | Â | 0.788 | Â | Â |
 < 8 | Reference |  |  |  |
 ≥ 8 | 1.1 (0.56–2.13) |  |  |  |
SUVmax-N | Â | 0.126 | Â | Â |
 < 6.4 | Reference |  |  |  |
 ≥ 6.4 | 1.71 (0.86–3.41) |  |  |  |
SUVmax-M | Â | 0.001 | Â | 0.004 |
 < 10 | Reference |  | Reference |  |
 ≥ 10 | 2.49 (1.45–4.27) |  | 2.10 (1.20–3.67) |  |
SUVmax-M-sum | Â | 0.002 | Â | Â |
 < 10 | Reference |  |  |  |
 ≥ 10 | 2.39 (1.36–4.21) |  |  |  |
SUVmax-M-mean | Â | 0.009 | Â | Â |
 < 8.8 | Reference |  |  |  |
 ≥ 8.8 | 2.07 (1.2–3.55) |  |  |  |